Papillary Thyroid Cancer: Diagnosis, Treatment & Variants

Papillary thyroid cancer is the most common type of thyroid cancer, accounting for the vast majority of thyroid cancer diagnoses, and it carries one of the highest survival rates of any cancer. Most people diagnosed with it will not die from it. But that reassuring headline conceals a more complicated reality: a massive wave of overdiagnosis driven by imaging technology, treatment decisions that range from removing the entire thyroid to simply watching and waiting, and a lived experience for patients that is far less breezy than the phrase “good cancer” implies.

Why So Many Cases Are Being Found

The global incidence of thyroid cancer has climbed sharply since the 1980s, yet mortality from the disease has stayed roughly flat. That gap between rising diagnoses and stable death rates is the hallmark of overdiagnosis, meaning cancers that are real under the microscope but would never have caused symptoms or shortened a person’s life if left undetected. The increase has been driven largely by the widespread and sometimes unnecessary use of imaging, especially neck and thyroid ultrasound, which picks up tiny papillary tumors that would otherwise go unnoticed.¹

A 2025 study modeling U.S. data from 1991 to 2019 estimated that somewhere between 72% and 94% of all papillary thyroid cancer cases diagnosed in that window were overdiagnosed. Women were hit harder: roughly 75% to 95% of female cases fell into the overdiagnosis category, compared with 63% to 90% among men. The absolute numbers are staggering, with the study estimating that between 443,000 and 574,000 women and 108,000 to 155,000 men received a papillary thyroid cancer diagnosis that did not affect population mortality over that period.² The same study modeled what would happen if referrals for ultrasound of nonpalpable nodules were reduced by a third or by two-thirds: incidence in 2019 would have dropped by about 17% or 41%, respectively, with less than a 0.1% change in overall mortality.³

This is not only an American phenomenon. A global analysis covering 2013 to 2017 found that about three-quarters of the 2.3 million thyroid cancer cases worldwide during that period were attributable to overdiagnosis, though the rate varied enormously by country. Some nations showed no overdiagnosis at all, while others, including South Korea, Cyprus, China, and Turkey, had overdiagnosis rates exceeding 85% in women.⁴ South Korea’s experience became a cautionary tale after a national screening program led to a fifteen-fold increase in thyroid cancer diagnoses with no change in deaths, prompting a public backlash and a subsequent drop in screening.

How Papillary Thyroid Cancer Is Found and Evaluated

Most papillary thyroid cancers today are discovered incidentally, either on an ultrasound performed for another reason or during a physical exam that happens to reveal a lump. Once a nodule is spotted, ultrasound features help stratify the risk. The most worrisome signs on ultrasound include spiculated or irregular margins, tiny flecks of calcium called microcalcifications, a shape that is taller than it is wide, and pronounced darkness compared with surrounding tissue.⁵ Based on these features, nodules are categorized into low-, intermediate-, or high-risk tiers, which guide whether a biopsy is recommended.

Biopsy is done with a fine needle (fine-needle aspiration), and the cells are examined under a microscope. Most samples come back clearly benign or clearly suspicious. But roughly 15% to 30% of biopsies land in an indeterminate gray zone, where the cells look neither obviously normal nor obviously cancerous. For those cases, molecular testing has become an increasingly useful tool. Two widely used platforms, one that reads RNA patterns and another that reads both DNA and RNA, can help sort out which indeterminate nodules are likely malignant and which are probably benign. A randomized trial found that these tests allowed nearly half of patients with indeterminate nodules to avoid a diagnostic surgery they would not have needed.⁶ A systematic review and meta-analysis of next-generation molecular tests found that the best-performing panel had an area under the curve of 0.95, meaning it was very good at correctly distinguishing cancerous from non-cancerous nodules.⁷

The Molecular Drivers Behind the Disease

Two genetic changes show up repeatedly in papillary thyroid cancer. The most common is a mutation in a gene called BRAF, specifically a single-letter swap known as BRAF V600E. This mutation activates a growth-signaling pathway in thyroid cells and is found in a large share of adult papillary thyroid cancers. Animal studies have shown that the BRAF V600E mutation can initiate tumor formation and drive its progression.⁸ In children, the mutation is less common, appearing in roughly 15% to 25% of cases in most populations, though rates are higher in parts of Asia.⁹

Whether the BRAF V600E mutation makes a given person’s cancer more dangerous has been debated for years. A large meta-analysis found that the mutation was linked to a moderately higher odds of lymph node spread and a borderline association with recurrence, but it showed no significant link to distant metastases or death from the disease.¹⁰ Interestingly, the more common the mutation was in the study population, the less useful it became for predicting who would do poorly, which suggests that having the mutation alone does not make someone high-risk. A separate study did find that patients with BRAF V600E had roughly triple the risk of recurrence compared with those without it, and that adding mutation status to existing prediction tools improved their accuracy.¹¹ In practice, clinicians use BRAF status as one factor among many rather than as a standalone decision-maker.

The second major genetic player is a group of rearrangements involving the RET gene, often shortened to RET/PTC. These rearrangements are strongly associated with radiation exposure. A meta-analysis confirmed that radiation exposure roughly tripled the odds of carrying a RET/PTC rearrangement, with one particular subtype, RET/PTC3, showing an eightfold increase in Western populations exposed to radiation.¹² This finding fits with what was observed after the Chernobyl disaster, where RET/PTC rearrangements were found in a high proportion of thyroid cancers that developed in children exposed to fallout.¹³ In children, a recently described category of genetic fusions involving the NTRK gene also appears in about 14% of pediatric thyroid cancers, opening the door to targeted therapy options.¹⁴

Surgery, and How Much of It

For decades, the default operation for papillary thyroid cancer was removing the entire thyroid gland. That has changed. Guidelines now recognize that for many patients with low- to intermediate-risk tumors, removing just the affected lobe (a lobectomy) achieves the same long-term survival as total thyroidectomy while substantially reducing complications.¹⁵ A systematic review and meta-analysis comparing the two approaches for intermediate-risk papillary thyroid cancer found no significant difference in overall survival, disease-specific survival, or recurrence-free survival. What did differ was the complication rate: lobectomy cut the overall risk of complications by roughly two-thirds, and it nearly eliminated the risk of temporary parathyroid dysfunction, a common side effect of total thyroidectomy that causes dangerously low calcium levels.¹⁶

Another debated question is whether to routinely remove central neck lymph nodes even when they look normal on imaging, a procedure called prophylactic central neck dissection. The evidence here is mixed. One meta-analysis found no meaningful reduction in local recurrence from the added dissection.¹⁷ A later and larger meta-analysis did find a significant reduction in central compartment recurrence, but at a cost: patients who had the extra dissection were more than twice as likely to develop temporary low calcium and had higher overall morbidity.¹⁸ The tradeoff is real, and current practice generally reserves prophylactic neck dissection for higher-risk patients or experienced surgical centers.

Active Surveillance Instead of Surgery

For very small, low-risk papillary thyroid cancers, a growing body of evidence supports skipping surgery altogether and instead monitoring the tumor with regular ultrasounds, an approach called active surveillance. Pioneered in Japan, this strategy is now endorsed by guidelines in multiple countries for carefully selected patients. A long-term study confirmed that active surveillance is a durable and safe management option, with older patients in particular showing even greater stability.¹⁹

One legitimate concern is what happens when patients stop showing up for monitoring. A study examining this found that even among patients who dropped out of follow-up entirely, none died from their papillary thyroid microcarcinoma, reinforcing just how slowly most of these tumors behave.²⁰ And if a tumor does grow or show signs of progression during surveillance, surgery performed at that point generally produces outcomes comparable to operating right away.²¹ Active surveillance is not for everyone. It requires comfort with uncertainty, reliable access to follow-up imaging, and a tumor that meets strict size and location criteria. But for those who qualify, it avoids surgery, hormone replacement, and the side effects that come with them.

Radioactive Iodine and Hormone Therapy After Surgery

After total thyroidectomy, patients may receive radioactive iodine to destroy any remaining thyroid tissue and potentially treat microscopic disease. Who benefits most from this step matters, because radioactive iodine is not a trivial treatment. A large observational study found that for tumors smaller than two centimeters, radioactive iodine did not improve disease-specific survival unless the patient had distant metastases. For tumors larger than two centimeters, the benefit became clearer when patients also had features like extrathyroidal extension, lymph node involvement, or were over 45.²² A systematic review of adjusted studies similarly found inconsistent benefits for low-risk patients already treated with surgery and thyroid hormone therapy, with some evidence of reduced locoregional recurrence but unclear impact on mortality in that group.²³

Nearly all patients who have their thyroid removed will take thyroid hormone replacement for the rest of their lives. In higher-risk patients, the dose is pushed high enough to suppress TSH, the hormone that stimulates thyroid tissue growth, on the theory that keeping TSH low discourages any residual cancer cells from growing. This TSH suppression approach does carry cardiovascular risks. A meta-analysis found that patients on TSH-suppressive therapy had roughly a 50% higher risk of atrial fibrillation compared with controls.²⁴ The consensus is to reserve aggressive suppression for patients whose cancer is high-risk or has recurred, and to keep suppression mild in low-risk patients to avoid unnecessary heart and bone complications.²⁵

Monitoring After Treatment

The primary tool for detecting recurrence after surgery is a blood test measuring thyroglobulin, a protein made by thyroid cells. After total thyroidectomy and radioactive iodine, thyroglobulin should become undetectable. If it rises, that signals possible recurrent disease. A study found that patients with undetectable thyroglobulin one year after treatment had only a 1% rate of later structural recurrence, compared with 38% among those with detectable levels.²⁶ That gap is large enough that some experts argue patients with undetectable thyroglobulin at one year may not need ongoing intensive surveillance.

For patients who had a lobectomy instead of total thyroidectomy, thyroglobulin monitoring works differently because normal thyroid tissue in the remaining lobe also produces the protein. In that context, researchers found that a thyroglobulin level above about 5 ng/mL measured six to twelve months after lobectomy roughly doubled the risk of recurrence. Patients whose most recent thyroglobulin rose above 11 ng/mL had a recurrence rate of about 24%, compared with about 4% for those below that cutoff.²⁷

Variants That Behave Differently

Not all papillary thyroid cancers are created equal under the microscope. The classical type is the most common and generally the most well-behaved. The tall-cell variant, which gets its name from the elongated shape of its tumor cells, has a reputation for being more aggressive. A meta-analysis confirmed that patients with the tall-cell variant had higher rates of spread beyond the thyroid, vascular invasion, lymph node and distant metastases, and worse overall survival compared with the classical type.²⁸

However, the tall-cell label is not an automatic death sentence. Tumor size and other features still matter. Research has shown that small tall-cell variant tumors, under two centimeters, without central lymph node involvement or multiple tumor foci carry a recurrence risk similar to classical papillary thyroid cancer and could potentially be managed with lobectomy alone.²⁹ Age also matters: the tall-cell morphology carries less prognostic weight in younger patients than in older ones.³⁰

When the Cancer Stops Responding to Radioactive Iodine

A minority of papillary thyroid cancers, particularly those that are advanced or have spread, eventually lose the ability to absorb iodine. This happens because the cell machinery that pulls iodine into thyroid cells, called the sodium iodide symporter, gets shut down or mislocated. The same genetic mutations that drive the cancer, including BRAF V600E and RET/PTC rearrangements, activate signaling pathways that progressively silence this iodine-uptake machinery.³¹ One study examining radioiodine-refractory papillary thyroid cancers found that the iodine symporter protein was completely absent in all refractory cases tested.³²

For these patients, targeted drugs called kinase inhibitors have changed the landscape. In the pivotal trial of lenvatinib versus placebo in radioiodine-refractory thyroid cancer, the drug extended the median time before the cancer worsened from about 3.6 months to 18.3 months, and nearly two-thirds of patients on the drug saw their tumors shrink.³³ These results are striking, but the side effects are significant. Real-world data showed that over 90% of patients experienced at least one serious side effect, most commonly severe high blood pressure, and about half had to stop the drug because of adverse effects.³⁴

Iodine Intake and Risk

The relationship between dietary iodine and papillary thyroid cancer is nuanced. Iodine is essential for thyroid function, and both deficiency and excess may influence thyroid cancer risk and the types of thyroid cancer that develop.³⁵ A case-control study found that people in the highest quarter of urinary iodine concentration had about a 50% higher risk of thyroid cancer compared with those in the lowest quarter. The association was strongest in women and in adults younger than 45, where the risk roughly doubled for those with the highest iodine levels.³⁶ This does not mean you should avoid iodized salt. Most people consume iodine in a range that is perfectly fine for thyroid health. The concern applies primarily to populations with very high iodine intake, such as those consuming large quantities of seaweed or certain supplements.

Family History and Inherited Risk

Most papillary thyroid cancer is considered sporadic, meaning it arises without a clear hereditary cause. But a small percentage of cases cluster in families. Familial non-medullary thyroid carcinoma, as it is called, can appear across generations and sometimes involves multiple first-degree relatives.³⁷ A large study comparing familial cases with sporadic ones found that the familial tumors tended to present more aggressively at diagnosis, showing up at more advanced stages, though long-term outcomes were not necessarily worse when treated appropriately.³⁸ If you have two or more close relatives with thyroid cancer, bringing that up with your doctor could lead to earlier screening and detection at a more treatable stage.

The “Good Cancer” Problem

Few phrases cause more harm in the thyroid cancer world than “good cancer.” Patients hear it constantly, from doctors, from friends, from the internet. A qualitative study found that the label came up unprompted from 94% of participants, mostly around the time of diagnosis. While the reassurance initially eased some anxiety, it also left people feeling that their fears were being dismissed. Patients described confusion when their personal experience, involving surgery, lifelong medication, fatigue, and ongoing worry, did not match the casual optimism implied by “good cancer.”³⁹

Research on early-onset thyroid cancer survivors has found significant effects on both physical and psychological well-being. Survivors reported feeling lost in the healthcare system, as if they could not access supportive services or have their struggles acknowledged because they had been told their cancer was the “good” kind.⁴⁰ A scoping review of the literature similarly concluded that anxiety, depression, and reduced quality of life are real and underaddressed in thyroid cancer survivors, undercutting the comfortable narrative.⁴¹ The survival statistics are genuinely encouraging, but they do not capture the full burden of living with a cancer diagnosis and its treatment.

Papillary Thyroid Cancer During Pregnancy

Papillary thyroid cancer is sometimes discovered during pregnancy, which is not surprising given that it disproportionately affects women of reproductive age and pregnancy involves neck examinations and sometimes ultrasounds. The disease-free survival among women diagnosed during pregnancy does not appear to differ from that of age-matched non-pregnant women with similar disease.⁴² In most cases, surgery can safely wait until after delivery. When surgery is performed during pregnancy, a study of 35 cases found favorable outcomes for both mother and child regardless of trimester, though early-pregnancy surgery carries extra considerations that call for a multidisciplinary team.⁴³ Radioactive iodine is absolutely off-limits during pregnancy, so any postoperative iodine treatment is deferred until after delivery and cessation of breastfeeding. Thyroid hormone dosing requires close monitoring to keep both the mother and fetus in a safe range.

Papillary Thyroid Cancer in Children

About 90% of differentiated thyroid cancers in children are the papillary type.⁴⁴ Pediatric papillary thyroid cancer behaves somewhat differently from the adult version. Children tend to present with more advanced disease at diagnosis, including higher rates of lymph node involvement and even lung metastases, yet paradoxically they often have excellent long-term outcomes. The molecular profile also differs: BRAF V600E mutations are less common in children, while gene fusions, including RET/PTC rearrangements and NTRK fusions, play a larger role. The identification of NTRK fusions in about 14% of pediatric cases is clinically relevant because drugs targeting NTRK are already approved and have shown activity in these tumors. Radiation exposure is a more prominent risk factor in children than in adults, a lesson underscored by the thyroid cancer cases that emerged in children after the Chernobyl and Fukushima nuclear events.

1
Nature Reviews Endocrinology. Unravelling the rise in thyroid cancer incidence and addressing overdiagnosis ↩︎
2
JAMA Network Open. Overdiagnosis of Papillary Thyroid Cancer ↩︎
3
JAMA Network Open. Overdiagnosis of Papillary Thyroid Cancer ↩︎
4
The Lancet Diabetes & Endocrinology. Global trends in thyroid cancer incidence and the contribution of diagnostic overdiagnosis ↩︎
5
PubMed Central. Risk Stratification of Thyroid Nodules: From Ultrasound Features to TIRADS ↩︎
6
JAMA Oncology. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial ↩︎
7
PubMed Central. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis ↩︎
8
PubMed. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications ↩︎
9
PubMed Central. Paediatric Thyroid Carcinoma: The Genetic Revolution and Its Implications for Therapy and Outcomes ↩︎
10
PubMed. Prognostic Value of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis of Nodal Involvement, Distant Metastases, Recurrence, and Mortality ↩︎
11
PubMed Central. BRAF V600E Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer Recurrence ↩︎
12
PubMed Central. Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis ↩︎
13
PubMed Central. RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma ↩︎
14
PubMed Central. Paediatric Thyroid Carcinoma: The Genetic Revolution and Its Implications for Therapy and Outcomes ↩︎
15
PubMed Central. Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer ↩︎
16
PubMed Central. The preferred surgical choice for intermediate-risk papillary thyroid cancer: total thyroidectomy or lobectomy? A systematic review and meta-analysis ↩︎
17
PubMed. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis ↩︎
18
PubMed. The Effect of Prophylactic Central Neck Dissection on Locoregional Recurrence in Papillary Thyroid Cancer After Total Thyroidectomy: A Systematic Review and Meta-Analysis ↩︎
19
JAMA Surgery. Long-Term Durability of Active Surveillance of Small, Low-Risk Papillary Thyroid Cancer ↩︎
20
PubMed Central. Active surveillance vs. surgery in low‐risk papillary thyroid microcarcinoma patients and the risk of loss to follow‐up ↩︎
21
iScience. Active surveillance for low-risk papillary thyroid carcinoma: Integrating guidelines, emerging evidence, and directions ↩︎
22
PubMed Central. The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER ↩︎
23
The Journal of Clinical Endocrinology & Metabolism. A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer ↩︎
24
PubMed Central. Meta-analysis of TSH suppression therapy and the risk of cardiovascular events after thyroid cancer surgery ↩︎
25
PubMed. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer ↩︎
26
PubMed. One-year Thyroglobulin Levels as a Predictive Measure for Recurrence and Need for Continued Surveillance in Treated Differentiated Thyroid Cancer ↩︎
27
PubMed. Predictive Value of Serum Thyroglobulin for Structural Recurrence Following Lobectomy for Papillary Thyroid Carcinoma ↩︎
28
PubMed Central. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis ↩︎
29
PubMed. Tumour size predicts risk of recurrence in tall cell subtype papillary thyroid carcinoma ↩︎
30
PubMed Central. Outcomes of the Tall-Cell Variant of Papillary Thyroid Carcinoma in Patients with Different Ages: A 17-Year Mono-Institutional Experience ↩︎
31
Theranostics. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS ↩︎
32
PubMed Central. The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF (V600E) Mutation ↩︎
33
New England Journal of Medicine. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer ↩︎
34
PubMed Central. Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects ↩︎
35
PubMed Central. Iodine nutrition and papillary thyroid cancer ↩︎
36
Scientific Reports. Association between urinary iodine concentration and the risk of papillary thyroid cancer by sex and age: a case–control study ↩︎
37
PubMed Central. Three siblings with familial non-medullary thyroid carcinoma: a case series ↩︎
38
PubMed Central. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers ↩︎
39
PubMed Central. Papillary Thyroid Cancer: The Good and Bad of the “Good Cancer” ↩︎
40
PubMed. “No such thing as good cancer”: a qualitative exploration of the experience of early-onset thyroid cancer in survivors ↩︎
41
PubMed Central. The “not so good” thyroid cancer: a scoping review on risk factors associated with anxiety, depression and quality of life ↩︎
42
PubMed Central. Management and follow-up of thyroid cancer in pregnant women ↩︎
43
PubMed. Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy ↩︎
44
PubMed Central. Paediatric Thyroid Carcinoma: The Genetic Revolution and Its Implications for Therapy and Outcomes ↩︎